Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain

Prostaglandins and Other Lipid Mediators

Volumn 70, Issue 1-2, 2002, Pages 1-12

  Paris, Daniel ^a   Townsend, Kirk P ^a   Obregon, Demian F ^a   Humphrey, James ^a   Mullan, Michael ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Brain slices; Cyclooxygenase; Inflammation; Microvessels; p38 MAPK; Prostaglandin

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMYLOID BETA PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN NERVE CELL; BRAIN SLICE; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; DRUG EFFECT; DRUG SOLUBILITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; MALE; NONHUMAN; PERICYTE; RAT; SMOOTH MUSCLE FIBER;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CATTLE; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; ISOENZYMES; MALE; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, SMOOTH MUSCLE; NITROBENZENES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; SOLUBILITY; SULFONAMIDES;

EID: 0036746143     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(02)00111-9     Document Type: Article

References (40)

1. Sisodia S.S., Price D.L. Role of the beta-amyloid protein in Alzheimer's disease. FASEB J. 9:1995;66-70.
2. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;8295-8298.
3. Naslund J., Haroutunian V., Mohs R.et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. J. Am. Med. Assoc. 283:2000;571-577.
4. Lue L.F., Kuo Y.M., Roher A.E.et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155:1999;853-862.
5. McLean C.A., Cherny R.A., Fraser F.W.et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46:1999;860-866.
6. Bazan N.G., Rodriguez de Turco E.B., Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J. Neurotrauma. 12:1995;791-814.
7. Ho L., Luterman J.D., Aisen P.S., Pasinetti G.M., Montine T.J., Morrow J.D. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 55:2000;323.
8. Montine T.J., Sidell K.R., Crews B.C.et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology. 53:1999;1495-1498.
9. Kitamura Y., Shimohama S., Koike H.et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254:1999;582-586.
10. Landolfi C., Soldo L., Polenzani L.et al. Inflammatory molecule release by beta-amyloid-treated T98G astrocytoma cells: role of prostaglandins and modulation by paracetamol. Eur. J. Pharmacol. 360:1998;55-64.
11. Paris D., Town T., Mori T., Parker T.A., Humphrey J., Mullan M. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol. Aging. 21:2000;183-197.
12. Diglio C.A., Liu W., Grammas P., Giacomelli F., Wiener J. Isolation and characterization of cerebral resistance vessel endothelium in culture. Tissue Cell. 25:1999;833-836.
13. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2317-2321.
14. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins. 47:1994;55-59.
15. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;7563-7568.
16. Ridley S.H., Dean J.L., Sarsfield S.J., Brook M., Clark A.R., Saklatvala J. A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Lett. 439:1998;75-80.
17. Manthey C.L., Wang S.W., Kinney S.D., Yao Z. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J. Leukoc. Biol. 64:1998;409-417.
18. Li Z., Jiang Y., Ulevitch R.J., Han J. The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem. Biophys. Res. Commun. 228:1996;334-340.
19. Kumar S., McDonnell P.C., Gum R.J., Hand A.T., Lee J.C., Young P.R. Novel homologues of CSBP/p38 MAP kinase: activation substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem. Biophys. Res. Commun. 235:1997;533-538.
20. Bhattacharyya D.K., Lecomte M., Dunn J., Morgans D.J., Smith W.L. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valeryl salicylic acid. Arch. Biochem. Biophys. 317:1995;19-24.
21. Andersen K., Launer L.J., Ott A., Hose A.W., Breteler M.M.B., Hofman A. Do non-steroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotteerdam study. Neurology. 45:1995;1441-1445.
22. Breitner J.C.S., Gau B.A., Welsh K.A., Plassman B.L., McDonald W.M., Helms M.J.et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 44:1994;227-232.
23. Meade E.A., Smith W.L., Dewitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 268:1993;6610-6614.
24. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease. J. Neuroimmunol. 24:1989;173-182.
25. McGeer P.L., McGeer E.G. Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukoc. Biol. 65:1999;409-415.
26. Huang T.H., Yang D.S., Plaskos N.P., Go S., Yip C.M., Fraser P.E.et al. Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J. Mol. Biol. 297:2000;73-87.
27. Ko L.W., Sheu K.V., Young O., Thaler H., Blass J.P. Expression in cultured human neuroblastoma cell of epitopes associated with affected neurons in Alzheimer's disease. Am. J. Pathol. 136:1990;867-879.
28. Gotti C., Briscini L., Verderio C., Oortgiesen M., Balestra B., Clementi F. Native nicotinic acetylcholine receptors in human Imr32 neuroblastoma cells: functional, immunological and pharmacological properties. Eur. J. Neurosci. 7:1995;2083-2092.
29. Paris D., Town T., Parker T.A.et al. Inhibition of Alzheimer's β-amyloid induced vasoactivity and microglial inflammatory response in microglia by a cGMP-dependent mechanism. Exp. Neurol. 157:1999;211-221.
30. Kim H.J., Kim K.W., Yu B.P., Chung H.Y. The effect of age on cyclooxygenase gene expression: NF-kappaB activation and IkappaBalpha degradation. Free Radic. Biol. Med. 28:2000;683-692.
31. Hensley K., Floyd R.A., Zheng N.Y.et al. p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 72:1999;2053-2058.
32. Hoffman S.W., Moore S., Ellis E.F. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. Stroke. 28:1997;844-849.
33. Li D.Y., Hardy P., Abran D.et al. Key role for cyclooxygenase-2 in PGE2 and PGF2alpha receptor regulation and cerebral blood flow of the newborn. Am. J. Physiol. 273:1997;R1283-R1290.
34. Rodriguez G., Nobili F., Copello F.et al. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. J. Nucl. Med. 40:1999;522-529.
35. Lee R.K., Knapp S., Wurtman R.J. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J. Neurosci. 19:1999;940-947.
36. Paris D., Town T., Mullan M. Novel strategies for opposing murine microglial activation. Neurosci. Lett. 278:2000;5-8.
37. Wenk G.L., McGann K., Mencarelli A., Hauss-Wegrzyniak B., Del Soldato P., Fiorucci S. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur. J. Pharmacol. 402:2000;77-85.
38. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 134:2000;58-65.
39. Bezzi P., Carmignoto G., Pasti L.et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 391:1998;281-285.
40. Lim G.P., Yang F., Chu T.et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20:2000;5709-5714.